Compare KRNY & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KRNY | STTK |
|---|---|---|
| Founded | 1884 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 511.9M | 569.1M |
| IPO Year | 2014 | 2020 |
| Metric | KRNY | STTK |
|---|---|---|
| Price | $8.06 | $7.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $8.50 | ★ $10.00 |
| AVG Volume (30 Days) | 257.6K | ★ 421.2K |
| Earning Date | 04-23-2026 | 05-01-2026 |
| Dividend Yield | ★ 5.33% | N/A |
| EPS Growth | ★ 130.22 | 53.02 |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $2,580,000.00 | $1,000,000.00 |
| Revenue This Year | $3.89 | N/A |
| Revenue Next Year | $17.52 | N/A |
| P/E Ratio | $27.50 | ★ N/A |
| Revenue Growth | ★ 36.00 | N/A |
| 52 Week Low | $5.76 | $0.71 |
| 52 Week High | $8.50 | $8.33 |
| Indicator | KRNY | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 55.49 | 55.06 |
| Support Level | $7.77 | $1.85 |
| Resistance Level | $8.27 | $7.68 |
| Average True Range (ATR) | 0.22 | 0.49 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 74.52 | 31.21 |
Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.